Collaborative Projects

Research and Development projects

PhagoBurn project

  • Beginning of project: 1st June 2013
  • Estimated timeline : 36 months
  • Global Budget : 5M€, of which 3,8 is European support
  • Clean Cells’ investment: 1,3M€

PhagoBurn Logo research and development

Phagoburn is a European research project, financed by the European commission, which is destined to evaluate phago therapy, the therapeutic use of bacteriophages, the natural viruses of bacteria.

This project aims at evaluating a therapy based on the use of two bacteriophage cocktails, for the treatment of burns infected by the bacteria, Escherichia coli and Pseudomonas aeruginosa, in clinical trial phase 1-2, carried out in France, Belgium and Switzerland.Furthermore, the results obtained in terms of efficacy and safety which will play a role in the drawing up of regulatory directive for phagotherapy.

The use of phages appears to offer great promise as a complementary treatment to antibiotics, due to the ever growing problem of antibiotic-resistant bacteria in the hospital environment.

The role of Clean Cells and the different partners

Phagoburn is a collaborative project that is made up of 5 principal partners from 3 different European countries:

  • The French Ministry of Defence (the co-ordinator of the project)by means of its Service for Military Health and The Percy Military hospital( The Burns Unit) .
  • The company Pherecydes Pharma (creator of the project) has chosen and developed the bacteriophage cocktails used in this project.
  • Clean Cells, is in charge of the production and the quality control of the bacteriophage cocktails in compliance with Good Manufacturing Practices (GMP).
  • The Royal Belgium Military Academy, in the Queen Astrid Military Hospital and more precisely its Burns Unit.
  • The Reference centre, the Serious Burns Unit in Lausanne (Switzerland), in the University Hospital Vaudois (CHUV).

The other groups involved in this project are : CHU Nantes (France), Centre hospitalier Saint Joseph et Saint Luc (France), Grand Hôpital de Charleroi – Loverval (Belgium), CHU Liège (Belgium), Statitec (France), PhagEspoirs (France), France Europe Innovation (France).

For more information :
PhagoBurn Project
Passeport Santé : Phagotherapie essais cliniques 


C4C project

  • Beginning of the project: March 2012
  • Global Budget: 80 M€, of which 30 M€ is financed by a programme of investment for the future.
  • Clean Cells’ investment: 1,3M€

Logo of C4C research and development project

C4C is a specific research and development project coordinated by the society CellForCure (a branch of the Laboratory of Biological fractionation – LFB) who aim to put in place the first French technical facility for the industrialisation of cell therapeutics. This project has been chosen as a National Research and development project as part of the Programme for investments in the future (PIA). This collaborative project has been co-approved by the centre, Atlanpole Biotherapies.

The objective is to produce cell therapeutics for autologous/allogeneic cell therapy projects and to validate the proof of concept by the production of 5 new medical therapies (ATMP).The final goal is to build the industrial sector of cell therapy in France.

Ultimately, this  research project will contribute to provide solutions for the treatment of numerous diseases, such as some types of diabetes or cancer: pericardial failure and incontinence would be treated in the future by replacing failing cells by functional cells.

The role of Clean Cells

Clean Cells is involved in this project for the development and validation of Quality Control methods dedicated to analyze the genetic stability of the Advanced Therapeutic Medicinal Product (ATMP). For this purpose, Clean Cells is providing an integrated service for karyotyping. With a highly skilled scientific team and innovative tools, Clean Cells is responding to quality issues closely associated with the industrialization of ATMP.

For more information :
Cell For Cure : C4C Project
Pacte PME : LFB Clean Cells


ADCC project

  • Beginning of the project: October 2011
  • Estimated timeline : 4 years
  • Global budget : 2,5 M€
  • Clean Cells’ investment: 1, 3 M€

The use of monoclonal antibodies was a major breakthrough in the treatment of a wide array of diseases, especially cancer, autoimmune, and inflammatory diseases. They constitute a major class of drugs and an increasing investment in the research and development and are deployed to generate new and innovative therapeutic antibodies.

In the context of the quality control of therapeutic antibodies, the project premium ADCC, coordinated by Clean Cells, aim to improve the tools to measure the antibody dependent cell cytotoxicity (ADCC) and to develop a non-radioactive standardized method, in compliance with the current regulatory requirements.

Clean Cells has established an agreement with the INSERM laboratory UMR892 from Nantes allowing the use of standardized ADCC effector cell population as an innovative tool to validate the therapeutic efficacy of antibodies. These effector cells are human modified lymphocyte T expressing the antigen CD16, which is the receptor of antibodies involved in the ADCC mechanism.

The Premium ADCC research program is focused on the optimization and standardization of the ADCC assay using these innovative effectors cells, and benefits from a financing scheme FUI (uniquely interministerial funds) involving Clean Cells, LFB Biotechnologies, INSERM UMR892 ( Nantes) and UMR CNRS 7292 GICC from Tours. Beyond the optimization and in the in depth characterization of these effectors cells, this program is also focused on the development of a non-radioactive ADCC measurement method.

The use of standardized effectors cells, in replacement of primary cells, purified from human blood currently used for such assays, brings to the forefront a new and relevant assay which answers the question of the reproducibility of the method, a key requirement in the measurement of a biological activity of therapeutic antibodies. The main area of application is in the screening of candidate therapeutics, and the batch release of antibody therapeutics, according to the regulatory requirements.

Furthermore, the ADCC non-radioactive method developed by Clean Cells, will have to reach the stringent requirements in term of sensitivity, accuracy and reproducibility, and reflect closely the ADCC biological process. Such a method fulfills the urgent need to reduce the current restrictions (contamination risk of the personnel and environment, management of supply and waste of radioactive material), linked to the use of 51Cr, the radioactive component used in the current reference method.

For more information:
Nantes développement : Recherches Clean Cells
Atlanpole Biotherapies : ADCC Project 


Catalogue Test

Our News & Events

  • Clean Cells’ Events

    In the third quarter, join the Clean Cells’ team at : Regmed Europe and NLSDays

  • Clean Cells’ Events

    Meet with Clean Cells. In the first quarter, join the Clean Cells’ team at the Centennial Celebration of Bacteiophage research…

  • Clean Cells’ Events

    Meet with Clean Cells. In the first quarter, join the Clean Cells’ team at :

  • Clean Cells’ Events

    Meet with Clean Cells. In the fourth quarter, join the Clean Cells’ team at :

  • Clean Cells’ Events

    In the third quarter, join the Clean Cells’ team at : ANTIBODY INDUSTRIAL SYMPOSIUM, EMBO CONFERENCE, BIOREGATE FORUM…

  • Clean Cells’ Newsletter

    Clean Cells is doing every to propose solutions that allow them to follow daily its activities. This is the reason why…

  • Of phages and men

    Clean Cells, as an authorized pharmaceutical facility, is now in position to offer its customers a wide panel of services for drug…

  • Clean Cells Tunes into Gene Therapy

    Clean Cells expands its service portfolio by tuning into gene therapy products since the beginning of 2015…

  • Clean Cells joins Come In Vendée

    Artists, merchants and companies from the Vendée that will unit to participate to the next Vendée Globe?…

  • Clean Cells’ Events

    In the second quarter, join the Clean Cells’ team at

  • Phage Therapy

    The Lancet ID published in november, 2015, a publication about PhagoBurn project, called “Phage therapy for severe infections…

  • ESGCT, Helsinki – Finland

    Dr Arnold Van der Luit will be attending the ESGCT (European Society of Gene and Cell Therapy), in Helsinki, Finland…

  • Workshop bacteriophages

    On 8 June 2015, the European Medicines Agency organized a workshop on the therapeutic use of bacteriophages…

  • Clean Cells’ New Office

    We are thus pleased to announce that we are setting up an new office in London, UK…

  • ESACT, Barcelona – Spain

    The Clean Cells team will be present at ESACT at booth 54. Visit us and learn more about our solutions for Biosafety Testing…